Inflammatory bowel disease: long-term therapeutic challenges.

Inflammatory bowel disease: long-term therapeutic challenges. Expert Rev Gastroenterol Hepatol. 2019 Oct 28;: Authors: Ashton JJ, Green Z, Kolimarala V, Beattie RM Abstract Introduction- Long-term, sustained, remission is the ultimate goal of contemporary inflammatory bowel disease therapy. Avoiding complications, surgery and malignancy, alongside minimising the side effects of medications are vital. However, the reality of treatment involves patients losing response to therapy, or developing complications requiring cessation of medication. The reasons for this are numerous and include medication and host-related influences. Underpinning the response to medication, long-term outcomes and loss of response are individual aetiological factors including the molecular cause of disease and individual pharmacogenomic influences. Areas covered- In this review we discuss the long-term outcome of inflammatory bowel disease, with a focus on paediatric-onset illness and discuss the factors leading to loss of treatment response and briefly consider the future of personalised therapy as a strategy to improve long-term outcome. Expert opinion- research findings are now moving towards clinical translation, including application of new medications targeting new pathways, alongside the integration of biological and multiomic data to predict disease outcome and personalise therapeutic response. PMID: 31657969 [PubMed - as supplied by publisher]
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research